TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9363264

Group type: EXPERIMENTAL
Intervention: Quinfamide at doses of 4.3 mg/kg b.i.d. in children and 100 mg t.i.d. in adults for one day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Etiamide at doses of 200 mg t.i.d. in children and 500 mg b.i.d. in adults for three days
Number of subjects: 110
Study: 1767803

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0
Study: 6445816

Group type: EXPERIMENTAL
Intervention: 1.5 percent solution of erythromycin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1.5 percent solution of erythromycin (continued therapy)
Number of subjects: 26
Study: 31535314

Group type: EXPERIMENTAL
Intervention: Machine learning super learner model
Number of subjects: 24178

Group type: COMPARATOR
Intervention: Logistic regression
Number of subjects: 24178

Group type: EXPERIMENTAL
Intervention: Super learner model
Number of subjects: 24178
Study: 31386114

Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study: 28319947

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 µg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 25886540

Group type: EXPERIMENTAL
Intervention: Individual lifestyle counseling (n=6091)
Number of subjects: 6091

Group type: COMPARATOR
Intervention: Control group (n=3324)
Number of subjects: 6091
Study: 24014906

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 88
Study: 21196831

Group type: EXPERIMENTAL
Intervention: Titanium cast in a pressure‐differential device (Cyclarc II, Morita)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cobalt‐chromium cast in a centrifugal machine (TS1, Degussa‐Hüls)
Number of subjects: 30
Study: 19436724

Group type: EXPERIMENTAL
Intervention: Dementia participants
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Diagnosis of Lewy body disorder
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: History of falls in the preceding 12 months
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Symptomatic orthostatic hypotension
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Autonomic symptom score
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Cornell depression score
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Higher levels of physical activity
Number of subjects: 179
Study: 16426289

Group type: EXPERIMENTAL
Intervention: Cream product preserved with diazolidinyl urea at varying concentrations
Number of subjects: 0
Study: 15296364

Group type: EXPERIMENTAL
Intervention: Sesamoid mobilization, flexor hallucis strengthening exercises, and gait training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment (whirlpool, ultrasound, first MPJ mobilizations, calf and hamstring stretching, marble pick-up exercise, cold packs, and electrical stimulation)
Number of subjects: 20
Study: 11367875

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus E. coli extract (LC-Extract)
Number of subjects: 164

Group type: COMPARATOR
Intervention: 5-fluorouracil plus placebo
Number of subjects: 164
Study: 9431482

Group type: EXPERIMENTAL
Intervention: Anthracycline-naive patients
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Anthracycline-treated patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 115
Study: 8055499

Group type: EXPERIMENTAL
Intervention: INTERPLAK Home Plaque‐Removal Instrument
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual brushing and flossing
Number of subjects: 30
Study: 3563413

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 1:3 ratio
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 3:1 ratio
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a long ileal segment (37.5 cm)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Jejunoileal bypass with a short ileal segment (12.5 cm)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unoperated patients
Number of subjects: 35
Study: 30196301

Group type: EXPERIMENTAL
Intervention: IV RetacritTM
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard-of-care (IV Epogen®)
Number of subjects: 432
Study: 25799211

Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholon (FML®) after capsulotomy in diabetic patients (Group 1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.1% Fluorometholon (FML®) after capsulotomy in non-diabetic patients (Group 3)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®) after capsulotomy in diabetic patients (Group 2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.5% ketorolac (Acular®) and 0.1% Fluorometholon (FML®) after capsulotomy in non-diabetic patients (Group 4)
Number of subjects: 88
Study: 24164587

Group type: EXPERIMENTAL
Intervention: Topical antibiotic prophylaxis
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Standard systemic antibiotic prophylaxis
Number of subjects: 1008
Study: 23377514

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 2813
Study: 20136458

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 14
Study: 16710026

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 200 microg every two weeks (Q2W)
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Epoetin alfa (EA) 40,000 units every week (QW)
Number of subjects: 1220

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) Q2W and Epoetin alfa (EA) QW
Number of subjects: 1220
Study: 15641864

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 8 mg daily for 8 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 21
Study: 11504166

Group type: EXPERIMENTAL
Intervention: Carvedilol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol plus ACE inhibitor (enalapril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitor alone
Number of subjects: 0
Study: 9785089

Group type: EXPERIMENTAL
Intervention: Local injection of macrophages prepared from a blood unit
Number of subjects: 199

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 199
Study: 7963169

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 43
Study: 3597168

Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30558152

Group type: EXPERIMENTAL
Intervention: C.H.A.M.P. Families intervention including eight group-based (parent-only) education sessions over 13-weeks, eight home-based activities, and two group-based (family) follow-up support sessions.
Number of subjects: 0
Study: 26883201

Group type: EXPERIMENTAL
Intervention: Decision aid leaflet
Number of subjects: 15844

Group type: COMPARATOR
Intervention: Usual invitation letter (Control)
Number of subjects: 15844

Group type: EXPERIMENTAL
Intervention: Previous attendance for screening
Number of subjects: 15844

Group type: EXPERIMENTAL
Intervention: Medium household income
Number of subjects: 15844
Study: 25539779

Group type: EXPERIMENTAL
Intervention: Community jury (n=12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 26
Study: 22584763

Group type: EXPERIMENTAL
Intervention: Automated identification with physician notification of modified systemic inflammatory response syndrome criteria
Number of subjects: 442

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 442
Study: 21077566

Group type: EXPERIMENTAL
Intervention: Constant contact technique with marshmallow roller tip
Number of subjects: 17

Group type: COMPARATOR
Intervention: Two-point touch technique with marshmallow tip
Number of subjects: 17
Study: 18662495

Group type: EXPERIMENTAL
Intervention: Exenatide before breakfast and dinner (BD)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Exenatide before lunch and dinner (LD)
Number of subjects: 377
Study: 15820346

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 41
Study: 15327343

Group type: EXPERIMENTAL
Intervention: Music therapy (3 blocks of single sessions over one year, 8 to 10 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 11383098

Group type: EXPERIMENTAL
Intervention: Hot packs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold packs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 9216364

Group type: EXPERIMENTAL
Intervention: Advanced nurse practitioner units
Number of subjects: 3

Group type: COMPARATOR
Intervention: Units without advanced nurse practitioners
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All units
Number of subjects: 3
Study: 7967359

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (subcutaneous infusion 50 mg/kg/12 hr)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (intravenous infusion 50 mg/kg/6 hr or 100 mg/kg/24 hr)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Desferrioxamine (both subcutaneous and intravenous)
Number of subjects: 19
Study: 3602281

Group type: EXPERIMENTAL
Intervention: Stressful movie
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutral movie
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-stress nights
Number of subjects: 11
Study: 31622733

Group type: EXPERIMENTAL
Intervention: Durvalumab, 10 mg/kg intravenously every 2 weeks for up to 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30701750

Group type: EXPERIMENTAL
Intervention: Remote blood pressure monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common practice of monitoring
Number of subjects: 0
Study: 27539685

Group type: EXPERIMENTAL
Intervention: Phosphate-buffered tirofiban (early phase, n=879)
Number of subjects: 3232

Group type: EXPERIMENTAL
Intervention: Citrate-buffered tirofiban (late phase, n=737)
Number of subjects: 3232

Group type: COMPARATOR
Intervention: Combined definition of thrombocytopenia (tirofiban vs. UFH)
Number of subjects: 3232

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 3232

Group type: COMPARATOR
Intervention: Phosphate-buffered tirofiban
Number of subjects: 3232
Study: 25642585

Group type: EXPERIMENTAL
Intervention: Excluded participants in the Cyberball game
Number of subjects: 40

Group type: COMPARATOR
Intervention: Included participants in the Cyberball game
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Excluded women
Number of subjects: 40

Group type: COMPARATOR
Intervention: Included women and excluded men
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 40
Study: 23040595

Group type: EXPERIMENTAL
Intervention: LVEF <40%
Number of subjects: 2430

Group type: COMPARATOR
Intervention: LVEF ≥40%
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: LVEF <30%
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: LVEF 30% to 40%
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: LVEF 40% to 50%
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: LVEF 50% to 60%
Number of subjects: 2430

Group type: EXPERIMENTAL
Intervention: LVEF ≥60%
Number of subjects: 2430
Study: 21969495

Group type: EXPERIMENTAL
Intervention: P-CAP (perifosine 50 mg orally once daily, days 1 to 21 and CAP 825 mg/m2 orally twice daily, days 1 to 14)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CAP (825 mg/m2 orally twice daily, days 1 to 14)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: P-CAP (subset analysis of fluorouracil-refractory patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CAP (subset analysis of fluorouracil-refractory patients)
Number of subjects: 38
Study: 18819175

Group type: EXPERIMENTAL
Intervention: Active treatment (prophylactic agent) with an Active Response Rate (ARR) of 50%
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo treatment with a Placebo Response Rate (PRR) of 25%
Number of subjects: 270
Study: 16918593

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (INH) administered preprandially using a metered-dose inhaler (MDI) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Insulin glargine (GLA) injected subcutaneously at bedtime for 4 weeks
Number of subjects: 24
Study: 12600857

Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (113 microg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Folic acid (100 microg)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 10987607

Group type: EXPERIMENTAL
Intervention: High-dose intravenous isosorbide-dinitrate (ISDN) 4 mg every 4 min (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BiPAP ventilation and standard dose nitrate therapy (n = 20)
Number of subjects: 40
Study: 8617895

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Computerized balance training (BT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Education (ED)
Number of subjects: 200
Study: 1333903

Group type: EXPERIMENTAL
Intervention: L-TAE with Farmorubicin (FARM)
Number of subjects: 117

Group type: COMPARATOR
Intervention: L-TAE with Adriamycin (ADR)
Number of subjects: 117
Study: 6711269

Group type: EXPERIMENTAL
Intervention: 40 ml of 0.5% mepivacaine with adrenaline (200 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 ml of 1% mepivacaine with adrenaline (400 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 ml of 1.5% mepivacaine with adrenaline (600 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of all groups
Number of subjects: 90
Study: 31162191

Group type: EXPERIMENTAL
Intervention: XueBiJing injection (100 mL, q12 hours)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: XueBiJing injection
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 28750059

Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: RG-TFV gel applied before and after receptive anal intercourse (RAI)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Overall adherence measurement
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Product PK results
Number of subjects: 187
Study: 24906790

Group type: EXPERIMENTAL
Intervention: Functional Remediation (FR), n=17
Number of subjects: 53

Group type: COMPARATOR
Intervention: Psychoeducation (PSY), n=19
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU), n=17
Number of subjects: 53
Study: 24282626

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg/day in a single dose for 7 days)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Ofloxacin (20 mg/kg/day in two divided doses for 7 days)
Number of subjects: 627
Study: 21954644

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g i.v. 3 times a day and amikacine 500 mg i.v. 2 times a day (Group 1A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g i.v. bolus, then permanent infusion 3 g per day and amikacine 15 mg/kg per day once a day (Group 1B)
Number of subjects: 40
Study: 19700988

Group type: EXPERIMENTAL
Intervention: PCEA (0.1% bupivacaine plus hydromorphone 10 mcg/mL at 8 mL/h plus bolus dosing)
Number of subjects: 38

Group type: COMPARATOR
Intervention: IV‐PCA (hydromorphone 2 mcg/kg/h continuous infusion; 2 mcg/kg bolus dose)
Number of subjects: 38
Study: 16916874

Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol and 1% clotrimazole ointment
Number of subjects: 374

Group type: COMPARATOR
Intervention: 1% chloramphenicol and placebo ointment
Number of subjects: 374
Study: 15675184

Group type: EXPERIMENTAL
Intervention: HGF plasmid DNA (three dose/regimens)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 11563497

Group type: EXPERIMENTAL
Intervention: Incandescent WALK sign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White LED WALK sign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue LED WALK sign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: White LED WALK sign with animated 'eyes' display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue LED WALK sign with animated 'eyes' display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incandescent WALK sign with animated 'eyes' display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (signals without animated 'eyes' display)
Number of subjects: 0
Study: 9425843

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole in the night before operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (did not receive lansoprazole)
Number of subjects: 50
Study: 8484550

Group type: EXPERIMENTAL
Intervention: Continuous supplemental inspired oxygen by nasal catheters [4 L/min] (Oxygen Group, n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No supplemental inspired oxygen (Control Group, n = 52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups (Oxygen Group and Control Group)
Number of subjects: 104
Study: 3318443

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg per day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Piroxicam 20 mg per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 45
Study: 30375301

Group type: EXPERIMENTAL
Intervention: Patients who never relapsed (21% of 178 patients)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Univariate predictors of non-relapse
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 178
Study: 29042390

Group type: EXPERIMENTAL
Intervention: POC culture and susceptibility testing (Flexicult SSI‐Urinary Kit)
Number of subjects: 191

Group type: COMPARATOR
Intervention: POC culture only (ID Flexicult)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: POC culture and susceptibility testing
Number of subjects: 191

Group type: COMPARATOR
Intervention: POC culture only
Number of subjects: 191
Study: 26100719

Group type: EXPERIMENTAL
Intervention: Usual care plus text messages timed to medication regimen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study: 23925738

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 82
Study: 22189640

Group type: EXPERIMENTAL
Intervention: AdperScotchbond Multi‐Purpose + resin cement RelyX ARC (SBMP+ARC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adper SingleBond 2 + RelyX ARC (SB+ARC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RelyX U100 self‐adhesive resin cement (U100)
Number of subjects: 48
Study: 19663111

Group type: EXPERIMENTAL
Intervention: Clindamycin-BP 2.5% gel
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Active ingredients (clindamycin or benzoyl peroxide)
Number of subjects: 2813

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 2813
Study: 16831503

Group type: EXPERIMENTAL
Intervention: Standard CPR training plus specific tuition on the characteristics of agonal breathing
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard CPR training
Number of subjects: 64
Study: 15488357

Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging influenza vaccinations
Number of subjects: 339220

Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging pneumonia vaccinations
Number of subjects: 339220

Group type: EXPERIMENTAL
Intervention: Direct mail marketing pieces encouraging influenza/pneumonia vaccinations
Number of subjects: 339220
Study: 12324782

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate and amoxicillin plus clavulanic acid
Number of subjects: 177

Group type: COMPARATOR
Intervention: 0.09% sterile saline solution
Number of subjects: 177
Study: 9502027

Group type: EXPERIMENTAL
Intervention: VENTEX Wound Dressing System (VWDS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Xeroform gauze
Number of subjects: 10
Study: 7636904

Group type: EXPERIMENTAL
Intervention: Normalization and maintenance of gastric mucosal pH (pHi) at or above 7.30
Number of subjects: 27

Group type: COMPARATOR
Intervention: Maintaining Oxygen Delivery Index (DO2I) of 600 and Oxygen Consumption Index (VO2I) of > 150
Number of subjects: 27
Study: 2702897

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Nutrition education plus social learning intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 78
Study: 580055

Group type: EXPERIMENTAL
Intervention: BAY g 2821 (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etacrynic acid (50 mg)
Number of subjects: 0
Study: 31012375

Group type: EXPERIMENTAL
Intervention: SAFE® program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group intervention
Number of subjects: 39
Study: 28962635

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control (placebo or best available therapy)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control (censored at crossover)
Number of subjects: 528
Study: 26126064

Group type: EXPERIMENTAL
Intervention: PURAP liquid-based pad
Number of subjects: 22
Study: 23964830

Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on alternate days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 10 mg of statin a day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on alternate days and 10 mg of statin a day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 200